1. Indications and Usage
\nGaucher Disease:
\nLong-term enzyme replacement therapy for patients with a confirmed diagnosis of non-neuropathic (Type 1) and chronic neuropathic (Type 3) Gaucher disease.
\nTarget Symptoms: Treatment of anemia, thrombocytopenia, bone disease, and hepatosplenomegaly (enlarged liver and spleen).
\n2. Dosage and Administration
\nRoute of Administration:
\nFor Intravenous (IV) Infusion ONLY.
\nRecommended Dosage:
\nIndividualized Dosing: Dosage is highly individualized based on disease severity and response.
\nTypical Range: Initial dosing typically ranges from 15 Units\/kg administered every 2 weeks to 60 Units\/kg administered every 2 weeks.
\nTitration: Dosage should be adjusted based on clinical response (e.g., reduction in spleen volume, increase in platelets).
\nCritical Administration Instructions:
\nReconstitution: Reconstitute with Sterile Water for Injection (2 mL for 200 Unit vial; 10 mL for 400 Unit vial).
\nDilution: Dilute the reconstituted solution in 0.9% Sodium Chloride Injection (100\u2013200 mL).
\nFiltration: Use an in-line low-protein-binding 0.2 \u00b5m filter.
\nInfusion Time: Administer over 1\u20132 hours.
\nStability: Do not freeze. Use immediately after reconstitution.
\n3. Mechanism of Action
\nEnzyme Replacement:
\nImiglucerase is a recombinant form of the human enzyme beta-glucocerebrosidase.
\nSubstrate Degradation:
\nIt catalyzes the hydrolysis of glucocerebroside (a lipid) into glucose and ceramide within the lysosomes of macrophages.
\nTherapeutic Result: By restoring enzymatic activity, it clears the accumulated “Gaucher cells” (lipid-laden macrophages) from the liver, spleen, and bone marrow, reversing organomegaly and cytopenias.
\n4. Safety and Warnings
\nHypersensitivity Reactions:
\nSerious hypersensitivity reactions (including anaphylaxis) have been reported.
\nAction: Monitor patients during infusion. Have appropriate medical support (e.g., epinephrine) available.
\nImmunogenicity:
\nPatients may develop IgG antibodies to imiglucerase.
\nAction: Monitor antibody titers, especially during the first year of therapy.
\nPulmonary Hypertension:
\nCases of pulmonary hypertension have been reported in patients treated with imiglucerase.
\nContraindications: None listed, but caution is advised in patients with severe pulmonary hypertension.
\n5.Adverse Reactions
\nMost Common:
\nInfusion-associated reactions (fever, chills, headache, dizziness, nausea), fatigue, bone pain, and injection site reactions.
\nNote: Most reactions are mild to moderate and can often be managed by slowing the infusion rate or pre-medication.
\n6.Drug Interactions
\nNo Clinical Significance:
\nNo formal drug-drug interaction studies have been conducted. However, caution is advised when co-administering with other drugs that may cause hypersensitivity.
\n7.Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Imiglucerase.
\nAppearance: White to off-white lyophilized cake or powder.
\nPackaging: Single-dose vial (200 Units and 400 Units).
\nStorage: Store at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F).<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name:\u601d\u800c\u8d5e\u00ae\uff08Cerezyme\u00ae\uff09
\nGeneric Name: Imiglucerase
\nStrength: 400 units per vial
\nManufacturer: Genzyme Ireland Ltd.
\nMarketing Authorization Holder: Genzyme Corporation (Sanofi Group)
\nDomestic Responsible Entity: Sanofi (China) Investment Co., Ltd.
\nApproval Date in China: 2014
\nRegistration Number: \u56fd\u836f\u51c6\u5b57SJ20140067
\nStorage: Store at 2\u20138\u00b0C, do not freeze, protect from light. Refer to the package insert for full storage specifications.<\/p>\n
Price&Cost:Contact Us now for the best price of Imiglucerase\uff08Cerezyme\uff09<\/p>\n","protected":false},"featured_media":4204,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[25],"product_tag":[],"class_list":["post-4203","product","type-product","status-publish","has-post-thumbnail","product_cat-injection","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n